Category Archives: Mesenchymal Stem Cells

Parkinson's Stem Cell Therapy - Group 28 pm BIOL 1103 Group 28 pm Stem Cell Application Assignment Sources: Euro Stem Cell research: http://www.eurostemcell.org Michael J. Fox Foundation: http://www.michaeljfox.org By: thehaysdays … Continue reading →

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR) today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2012, on Wednesday, March 6, 2013. C. Randal Mills, Ph.D., President and Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Financial Officer, will provide a company update and discuss results via a webcast and conference call on Wednesday, March 6, 2013 at 9:00 a.m. ET. To access the webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm. Alternatively, callers may participate in the conference call by dialing (877) 303-6133 (U.S. participants) or (970) 315-0493 (international participants). An archive of the webcast will be available approximately two hours after the completion of the call. To access the archived webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm. About Osiris Therapeutics Osiris Therapeutics, Inc., having developed the worlds first approved stem cell drug, Prochymal, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. In Biosurgery, Osiris currently markets Grafix for burns and chronic wounds, and Ovation for orthopedic applications. Osiris is … Continue reading →

A University of Texas spinoff company has pulled in $2 million to test a new technique for culturing non-embryonic stem cells. According to a regulatory filing, StemBioSys raised at least $2 million of a $3.5 million equity offering. A company representative was not available to elaborate, but CEO Dr. Steven Davis told the San Antonio Business Journal last year when the company began raising the round that it would fund research projects to validate the quality of the stem cells generated by the companys technology. StemBioSys is developing XC-marrow ECM, a propriety three-dimensional culture for growing mesenchymal stem cells from bone marrow, adipose tissue and umbilical cord blood. These immature cells have multiple potential uses in research and therapeutics because they can self-renew and mature into a variety of cell types. Stem cell therapies are being studied as a repair mechanism for tissues all over the body, from the heart to the brain to the knees. The company says its three-dimensional extracellular matrix can grow cells quicker than conventional media while retaining stem cell properties and may help overcome key obstacles in creating stem cell therapies. The technology was developed by Dr. Xiao-Dong Chen, an associate professor of medicine at … Continue reading →

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), the leading stem cell company developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that the European Medicines Agency (EMA) has designated Osiris as the Orphan Drug title holder for Prochymal (remestemcel-L). The EU Commission adopted the decision to transfer the designation of Prochymal (ex-vivo cultured adult human mesenchymal stem cells) as an orphan medicinal product under Regulation (EC) No 141/2000 of the European Parliament and of the Council. The Decision will appear in the EU Community Register of Orphan Medicinal Products. In Europe, Orphan Drug designation provides a variety of incentives, including market exclusivity for up to 10 years following approval, to companies that develop drugs for underserved patient populations. In the EU, the Orphan Drug designation for Prochymal is for the treatment of acute graft versus host disease (GvHD). Prochymal, a first-in-class allogeneic stem cell therapy, has already received approval in Canada and New Zealand for the treatment of acute GvHD in children, and is currently available in seven other countries including the United States under an Expanded Access Program (EAP). Recently, Swissmedic, the Swiss agency responsible for the evaluation of drugs, … Continue reading →

Washington, February 14 (ANI): Scientists have identified a pivotal protein in a cellular transformation that makes a cancer cell more resistant to treatment and more capable of growing and spreading, making it an inviting new target for drug development. Additionally, the international team led by scientists at The University of Texas MD Anderson Cancer Center found the cancer drug sunitinib potentially has a new role in treating triple-negative, claudin-low breast cancer, a particularly resistant version of a type of cancer that is already difficult to treat. "We found that FOXC2 lies at the crossroads of the cellular properties of cancer stem cells and cells that have undergone epithelial to mesenchymal transition (EMT), a process of cellular change associated with generating cancer stem cells," said senior author Sendurai Mani, Ph.D., assistant professor in MD Anderson's Department of Translational Molecular Pathology and co-director of the Metastasis Research Center. Cancer stem cells are fewer in number than other tumor cells, yet research has tied them to cancer progression and resistance to treatment. Abnormal activation of the epithelial to mesenchymal transition can create cancer stem cells, Mani noted. "There are multiple molecular pathways that activate EMT. We found many of these pathways also activate … Continue reading →

Leggos for stem cells... you've got to be kidding! http://www.stemcellsarthritistreatment.com Stem cell arthritis treatment depends on a number of important factors. These include the mesenchymal stem cells themselves, growth factors, and a scaffold. Stem cell therapy for arthritis requires all of these to be successful. Peptides are amino acids which are the building blocks of proteins. They can be assembled into scaffolds and have the advantages of being both reproducible as well as functional. Sort of like Leggos. Go to http://www.stemcellsarthritistreatment.com and sign up to receive a free portfolio of valuable information on stem cell arthritis treatment. http By: Nathan Wei … Continue reading →

Fearing that unscrupulous use may hijack this promising field, stakeholders are racing to regulate its applications. Are they swift enough? Image: Mallikarjun Katakol for Forbes India Stempeutics Researchs CEO BN Manohar: While we work till science matures, others [stem -cells clinics] are making money from day one We dont do clinical trials, we provide commercial stem-cell therapy, says an executive of a Pune-based company on the phone when we inquire about participating in one to avail the treatment that its website boldly speaks of. If you cant come in person, send us your case study in email and well advise you how many infusions of stem cells your patient would require, he suggests. The companys website says it has provided 1,000 infusions to patients and is a leader in stem-cells therapy. The so-called therapy costs upwards of Rs 2-3 lakh, the executive discloses on persuasion. This Pune clinic is only one among the many that peddle the unproven stem-cell therapy. They are supposed to enrol patients under a proper clinical trial; instead they get by with merely adding the word experimental to their offerings. You wont find these clinics on the clinical trial registry of the Indian Council of Medical … Continue reading →

Feb. 11, 2013 Geneticists led by University of Utah Nobel Prize Laureate Mario R. Capecchi, Ph.D., have engineered mice that develop clear cell sarcoma (CCS), a significant step in better understanding how this rare and deadly soft tissue cancer arises. The mouse model also can potentially speed the development of drugs to target genes that must be activated for the cancer to form. CCS arises in connective soft tissues, such as tendons, fat, blood vessels, and muscle. Researchers have known that the first step in the process that leads to CCS occurs when two human chromosomes, 12 and 22, randomly break after DNA gets damaged from the effects of sunlight or other causes. Each chromosome usually harmlessly rejoins after breaking. But occasionally part of one chromosome will join with part of the other to create a new gene called a fusion gene. When this gene, ews-atf1 is generated, it initiates the process that causes CCS. The rare and aggressive nature of sarcomas, and their occurrence in children and young adults, long has interested Capecchi. In a study in the Feb. 11, 2013, online edition of Cancer Cell, he and colleagues from the University of Utah, the University of Texas M.D. … Continue reading →

Fearing that unscrupulous use may hijack this promising field, stakeholders are racing to regulate its applications. Are they swift enough? Image: Mallikarjun Katakol for Forbes India Stempeutics Researchs CEO BN Manohar: While we work till science matures, others [stem -cells clinics] are making money from day one We dont do clinical trials, we provide commercial stem-cell therapy, says an executive of a Pune-based company on the phone when we inquire about participating in one to avail the treatment that its website boldly speaks of. If you cant come in person, send us your case study in email and well advise you how many infusions of stem cells your patient would require, he suggests. The companys website says it has provided 1,000 infusions to patients and is a leader in stem-cells therapy. The so-called therapy costs upwards of Rs 2-3 lakh, the executive discloses on persuasion. This Pune clinic is only one among the many that peddle the unproven stem-cell therapy. They are supposed to enrol patients under a proper clinical trial; instead they get by with merely adding the word experimental to their offerings. You wont find these clinics on the clinical trial registry of the Indian Council of Medical … Continue reading →

Stem Cell Therapy Testimonial - Arthritis 1-888-545-4333 Stem Cell Therapy Testimonial - Arthritis 1-888-545-4333 By: Bofitmiami … Continue reading →